Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040451 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTALDH1A1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL31193341 | 0.97 | CYP3A4 (0.56) | CYP3A4MAPTALDH1A1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL9871800 | 0.97 | CYP3A4 (0.56) | CYP3A4MAPTALDH1A1HTR2AHTR2C | |
| SCHEMBL6122379 | 0.84 | POLB (0.47) | CYP3A4MAPTALDH1A1HTR2AHTR2C | |
| SCHEMBL29788066 | 0.84 | HTR2A (0.61) | CYP3A4MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL382917 | 0.84 | HTR2C (0.50) | CYP3A4MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL8794833 | 0.84 | CHRNA7 (0.49) | CYP3A4MAPTALDH1A1MAOACHRNA7 | |
| SCHEMBL329913 | 0.84 | HTR2A (0.61) | CYP3A4MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL30677786 | 0.84 | HTR2C (0.67) | CYP3A4MAPTALDH1A1HTR2AHTR2C | |
| SCHEMBL13028005 | 0.84 | MAPT (0.43) | CYP3A4MAPTALDH1A1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0186187-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-02 | — | — | EP | claimed |
| WO-2024149360-A1 | BIQUATERNARY AMMONIUM SALT COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | 西藏海思科制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-116987021-A | Novel isoindoline derivative with anti-tumor effect as well as preparation method and application thereof | 北京中医药大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115286616-A | Tetrahydroisoquinoline and isoindoline compound capable of binding sigma-2 receptor, preparation method and application thereof | 北京师范大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-107849047-B | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3153515-B1 | COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AB PHARMA LTD (CN) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020108688-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR NUCLEAR-MEDICAL IMAGING | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020029980-A1 | SMAD3 INHIBITORS | MOEXA PHARMACEUTICALS LIMITED (CN) | 2020-02-13 | — | — | WO | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
| US-4987235-A | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
| EP-0227986-A1 | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
| US-4677100-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-06-30 | — | — | US | disclosed |
| EP-0186187-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | CYP3A4 3288/4885MAPT 3491/4885ALDH1A1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.